Exsilio Therapeutics launches with $82 million Series A Financing for the Development of Redosable Genomic Medicines to Treat a Broad Range Of Diseases October 3, 2024 Read More
Silicon Valley’s latest feud: David Sacks, Parker Conrad, Paul Graham, others spar over VC ethics on X October 2, 2024 Read More